AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ATRC - AtriCure, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$51.33
DETAILS
HIGH:
$55.00
LOW:
$44.00
MEDIAN:
$55.00
CONSENSUS:
$51.33
UPSIDE:
81.44%
Stock News
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure NASDAQ: ATRC executives said the company's 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding opportunities in pain management and appendage management.
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q1 Earnings
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AtriCure (ATRC) Reports Break-Even Earnings for Q1
AtriCure (ATRC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
AtriCure Reports First Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2026 financial results. “Our first quarter results reflect the durability of AtriCure's growth model, fueled by disciplined execution and increased adoption of our innovative products,” said Michael Carrel, President and Chief Executive Officer.
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Bank of America Securities Health Care Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, May 12, 2026, at 10:00 a.m. Pacific Daylight Time. Interested par.
Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts
Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.
AtriCure to Announce First Quarter 2026 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to discuss its first quarter financial results. Those interested in listening to th.
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
ArtiCure Chief Science Officer sold 5,000 shares for a transaction value of approximately $149,000 at around $29.83 per share on March 12, 2026. The sale represented 4.91% of Vinayak's direct holdings, reducing direct ownership from 101,875 to 96,875 shares.
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of “Moderate Buy” from Analysts
Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have given a buy recommendation to the company.
Citigroup Inc. Purchases 36,839 Shares of AtriCure, Inc. $ATRC
Citigroup Inc. raised its position in AtriCure, Inc. (NASDAQ: ATRC) by 182.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,085 shares of the medical device company's stock after purchasing an additional 36,839 shares during the period. Citigroup
AtriCure to Participate in the Citizens Life Sciences Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Citizens Life Sciences Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, March 10, 2026, at 1:05 p.m. Eastern Time. Interested parties may access a live audio.
AtriCure Q4 Earnings Call Highlights
AtriCure (NASDAQ: ATRC) reported fourth-quarter and full-year 2025 results that management said reflected accelerating growth in several core franchises, improving profitability, and progress on major clinical and product development initiatives. The company also reaffirmed its 2026 outlook for 12% to 14% revenue growth. Full-year and fourth-quarter financial results For full-year 2025, AtriCure posted worldwide revenue of
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q4 2025 Earnings Call Transcript
AtriCure (ATRC) Tops Q4 Earnings and Revenue Estimates
AtriCure (ATRC) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.08 per share a year ago.
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2025 and full year 2025 financial results. “Our 2025 performance reflects strong execution and continued momentum in our business. We delivered 15% revenue growth for the year and strengthened profitability while advancing key innovation and c.
AtriCure (NASDAQ:ATRC) Shares Gap Down Following Analyst Downgrade
AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) gapped down before the market opened on Wednesday after JPMorgan Chase and Co. downgraded the stock from an overweight rating to a neutral rating. The stock had previously closed at $37.86, but opened at $34.00. JPMorgan Chase and Co. now has a $36.00 price target on the stock.
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Price Targets
AtriCure price target raised to $55 from $53 at Canaccord
$55.00
(was $28.59)
Canaccord Genuity
AtriCure price target lowered to $55 from $60 at UBS
$55.00
(was $32.97)
UBS
AtriCure price target lowered to $53 from $64 at Canaccord
$53.00
(was $32.97)
William Plovanic
·
Canaccord Genuity
AtriCure downgraded to Perform from Outperform at Oppenheimer
$44.00
(was $32.97)
Oppenheimer
AtriCure Inc. (ATRC) PT Raised to $64 at Canaccord Genuity
$64.00
(was $35.44)
William Plovanic
·
Canaccord Genuity
AtriCure price target raised to $54 from $52 at BTIG
$54.00
(was $35.13)
BTIG
AtriCure price target lowered to $26 from $30 at Stifel
$26.00
(was $22.00)
Rick Wise
·
Stifel Nicolaus
AtriCure price target lowered to $40 from $65 at Piper Sandler
$40.00
(was $22.00)
Matt O'Brien
·
Piper Sandler
AtriCure Inc. (ATRC) PT Lowered to $53 at BTIG
$53.00
(was $22.00)
Marie Thibault
·
BTIG
AtriCure Inc. (ATRC) PT Lowered to $40 at Needham
$40.00
(was $24.76)
Mike Matson
·
Needham
AtriCure Inc. (ATRC) PT Lowered to $58 at BTIG
$58.00
(was $24.76)
Marie Thibault
·
BTIG
Oppenheimer Upgrades AtriCure Inc. (ATRC) to Outperform
$32.00
(was $22.71)
Suraj Kalia
·
Oppenheimer
Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $81
$81.00
(was $47.20)
Canaccord Genuity
AtriCure price target raised to $58 from $55 at Needham
$58.00
(was $41.37)
Mike Matson
·
Needham
AtriCure price target lowered to $55 from $90 at Piper Sandler
$55.00
(was $49.69)
Matt O'Brien
·
Piper Sandler
Needham Maintains Buy on AtriCure, Lowers Price Target to $67
$67.00
(was $54.63)
Needham
SVB Leerink Maintains Outperform on AtriCure, Lowers Price Target to $75
$75.00
(was $54.63)
Leerink Partners